DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life

Information source: Postgraduate Institute of Medical Education and Research
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Minimal Hepatic Encephalopathy; Hepatic Encephalopathy

Intervention: Lactulose (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Postgraduate Institute of Medical Education and Research

Official(s) and/or principal investigator(s):
Radha K Dhiman, MD,DM, FACG, Principal Investigator, Affiliation: Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India

Summary

Minimal hepatic encephalopathy (MHE) has a negative effect on patients’ daily functioning. No study has so far investigated the effect of treatment related improvement in cognitive functions on health related quality-of-life (HRQOL). This study was carried out to determine the influence of treatment on psychomotor performance and on HRQOL in patients with MHE.

The mean number of abnormal NP tests decreased significantly in patients in treated group compared with patients in untreated group MANOVA for time and treatment, P =.001). Mean total SIP score improved among patients in the treated group after 3 months compared with patients in untreated group after 3 months (MANOVA for time and treatment, P=.002). Improvement in HRQOL was related to the improvement in psychometry. In conclusion, treatment with lactulose improves both cognitive functions and HRQOL in cirrhotic patients with MHE.

Clinical Details

Study design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Efficacy Study

Primary outcome: Improvement in minimal hepatic encephalopathy and health related quality of life

Detailed description: The study has been published in March 2007 in Hepatology

Lactulose Improves Cognitive Functions and Health-Related Quality of Life in Patients with Cirrhosis WhoHave Minimal Hepatic Encephalopathy. Srinivasa Prasad, Radha K. Dhiman, Ajay Duseja, Yogesh K. Chawla, Arpita Sharma, and Ritesh Agarwal. (HEPATOLOGY 2007;45: 549-559.)

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All the patients diagnosed as having cirrhosis of liver

Exclusion Criteria:

- Overt HE or a history of overt HE;

- History of recent (< 6 weeks) alcohol intake;

- Infection, recent (< 6 weeks) antibiotic use or gastrointestinal bleeding;

- History of recent (< 6 weeks) use of drugs affecting psychometric

- Performances like benzodiazepens, antiepileptics, psychotropic drugs;

- History of shunt surgery or transjugular intrahepatic portosystemic shunt for portal

hypertension;

- Electrolyte imbalance;

- Renal impairment;

- Presence of hepatocellular carcinoma;

- Severe medical problems such as congestive heart failure, pulmonary disease,

neurological or psychiatric disorder, etc., that could influence quality-of-life measurement;

- Inability to perform NP tests and to complete the SIP questionnaire due to bad

vision.

Locations and Contacts

Postgraduate Institute of Medical Education and Research, Chandigarh, UT 160012, India
Additional Information

Starting date: January 2004
Ending date: December 2004
Last updated: March 1, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009